Panel discussion
Shahriar Islam, London / United Kingdom
Sergey Morozov, Brussels / Belgium
Catherine Mary Jones, Brisbane / Australia
Luis Marti-Bonmati, Valencia / Spain
- To clarify current FDA regulatory pathways for AI/ML-based medical devices.
- To discuss evolving reimbursement models for AI-augmented radiology services.
- To address medicolegal considerations and liability distribution between radiologists, institutions, and AI vendors.
- To explore international regulatory harmonization efforts.
- To examine the role of continuous learning algorithms and post-market surveillance.